Board Member
Lyra Therapeutics, Inc.
Equibles does not estimate personal net worth.
Maria Palasis is recorded as Board Member at Lyra Therapeutics, Inc. since January 1, 2015. The newest filing on record that lists Maria Palasis as Board Member at Lyra Therapeutics, Inc. is dated April 4, 2025. Lyra Therapeutics, Inc. reported in an 8-K filed January 12, 2026 that Maria Palasis was terminated as Chairman of the Board, effective January 9, 2026. Lyra Therapeutics, Inc. reported in an 8-K filed January 12, 2026 that Maria Palasis was terminated as Chief Executive Officer, effective January 9, 2026. The proxy statement of Lyra Therapeutics, Inc. reports total compensation of $1,735,751 for Maria Palasis in fiscal 2022, including a base salary of $583,000. Disclosed compensation is on record for 4 fiscal years. Maria Palasis has spoken on 5 earnings calls across 1 company, most recently for Lyra Therapeutics, Inc. on November 9, 2021. Lyra Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector.
“On January 9, 2026, in connection with the Plan described in Item 2.05, the employment of Dr. Maria Palasis, the Company's Chief Executive Officer, President and Chairman of the Board, and of Mr. Jason Cavalier, the Company's Chief Financial Officer and Treasurer, was terminated.”
“On January 9, 2026, in connection with the Plan described in Item 2.05, the employment of Dr. Maria Palasis, the Company's Chief Executive Officer, President and Chairman of the Board, and of Mr. Jason Cavalier, the Company's Chief Financial Officer and Treasurer, was terminated.”
“This third quarter of 2021 was another quarter of significant progress at Lyra. On the clinical front, we continue to generate data that strengthens the profile of our lead candidate, LYR-210, for the treatment of chronic rhinosinusitis.”
“As you heard, we are sufficiently funded to drive all our clinical programs forward into next year. We are at an exciting inflection point in Lyra’s evolution. We have strong validation of our technology and our first indication and several important catalysts on the horizon.”
“And welcome everyone to Lyra Therapeutics first quarter 2021 financial results conference call. As a reminder, Lyra Therapeutics' goal is to transform the ENT treatment paradigm by providing effective solutions for physicians and new treatment options for their patients.”
“And welcome, everyone to Lyra's Therapeutics fourth quarter and full year 2020 financial results conference call.”
“Let me start by saying how delighted I am to welcome you to Lyra's second quarter 2020 financial results conference call, which is our very first as a public company.”
Lyra Therapeutics, Inc.
Board Member
Proxy statement
2015-01-01–present
Last confirmed April 4, 2025
Lyra Therapeutics, Inc.
CEO
Proxy statement
Start not stated–2026-01-09
Lyra Therapeutics, Inc.
Biotechnology · Healthcare
Board Member
2015-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Lyra Therapeutics, Inc. | President and Chief Executive Officer | $583,000 | $1,735,751 |
| 2021 | Lyra Therapeutics, Inc. | President and Chief Executive Officer | $552,115 | $1,754,599 |
| 2020 | Lyra Therapeutics, Inc. | President and Chief Executive Officer | $470,520 | $4,301,741 |
| 2019 | Lyra Therapeutics, Inc. | President and Chief Executive Officer | $388,025 | $842,684 |
Lyra Therapeutics, Inc. Q3 FY2021 Earnings Call
Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc. Q2 FY2021 Earnings Call
Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc. Q1 FY2021 Earnings Call
Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc. Q4 FY2020 Earnings Call
Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc. Q2 FY2020 Earnings Call
Lyra Therapeutics, Inc.
